Subscribe to RSS



Antares Pharma Inc. (NASDAQ:ATRS) Declares 4Q Loss swells on Otrexup Expenses – ATRS, MELA, BDX, COV, HTWR

Antares Pharma Inc. (NASDAQ:ATRS)’s shares plunged more than 4% in last trading hours after it declared Q4 loss increased as the drug developer spent a lot to prepare its possible rheumatoid arthritis treatment Otrexup for narrow appraisal.

The Ewing, N.J., firm declared on Wednesday that it lost $5M, or 4 cents a share, in the quarter that ended Dec. 31. That evaluates to a loss of $154,000, or lowers than 1 cent a share, in the final quarter of 2011, at what time it had fewer shares outstanding. Revenue rose around 1% to $5.5M.

Analysts anticipated, on average, a loss of 3 cents a share on $5.3M in revenue, according to FactSet.

Antares lost $11.4M, or 10 cents a share for the full year, on $22.6M in revenue.

The firm reported that it ended the year with $85.2M in cash and investments and no debt.

Antares Pharma Inc (NASDAQ:ATRS) stock hit highest price at $3.62, beginning with a price of $3.59 and reported decreased -4.17% to the closed at $3.45 with day range of $3.43-$3.62. The total market capitalization remained $431.75 million, total volume held in the session was 1.14 million shares surprisingly higher than its average volume of 859,319 shares.

To check the Stocks ups and downs, ATRS last week stock price volatility remained 4.70% and month was at 4.16%. ATRS generated revenue of 22.50 million in the following twelve months income of -$6.57 million. The Company showed a negative -29.20% in the net profit margin and in addition to in its operating margin which remained -29.19%. Company’s annual sales growth for the past five year was 30.99%.

The ATRS past twelve months price to sales ratio was 19.19 and price to cash ratio remained 14.29. As far as if notice on other major contributors of similar sectors have sale ratio and price to cash ratio remained MELA Sciences Inc (NASDAQ:MELA)’s P/S 172.16% P/C 6.13%, Becton, Dickinson and Co. (NYSE:BDX)’s P/S 2.27% P/C 7.03%, Covidien plc (NYSE:COV)’s P/S 2.59% P/C 22.28%, HeartWare International Inc (NASDAQ:HTWR)’s P/S 11.75% P/C 12.68%.


Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here

0 comments

Other articlesgo to homepage

On-top Session Stocks: BioFuel Energy Corp (Nasdaq:BIOF), LiveDeal Inc (Nasdaq:LIVE), Insteel Industries Inc (Nasdaq:IIIN), SGOCO Group Ltd (Nasdaq:SGOC), SanDisk Corp (Nasdaq:SNDK)

On-top Session Stocks: BioFuel Energy Corp (Nasdaq:BIOF), LiveDeal Inc (Nasdaq:LIVE), Insteel Industries Inc (Nasdaq:IIIN), SGOCO Group Ltd (Nasdaq:SGOC), SanDisk Corp (Nasdaq:SNDK)

Shares of BioFuel Energy Corp. (Nasdaq:BIOF) skyrocketed on Thursday’s market activity, currently trading for about $8.20, up $2.14 (or +35.30%), and 5,845,868 of its shares exchanged hands so far BioFuel Energy recently received a preliminary non-binding proposal, which suggested the company acquire acquire all of the equity interests in real-estate developer JBGL Capital and JBGL

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Shares of Zalicus Inc. (Nasdaq:ZLCS) skyrocketed $0.32 (or +31.07%) to $1.35, following the announcement that Epirus Biopharmaceuticals, Inc., which has closed a $36 million Series B financing round, will merge with a wholly-owned subsidiary of Zalicus, to create a global biosimilar enterprise. 13,616,255 shares of Zalicus were traded on Wednesday, increased activity versus its average

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

The trading levels of SmartPros Ltd. (Nasdaq:SPRO) stock exploded on Monday’s market activity, closing at $2.99, up $0.77 (or +34.68%), and 334,315 of its shares exchanged hands during the day, a large increase on activity versus its average volume (3m) of 7,818 On intraday trading, SPRO stock reached a new 52 week high of $3.30

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Shares of JAKKS Pacific, Inc. (Nasdaq:JAKK) soared $0.75 (or +9.96%) to $8.28, and 1,043,882 of its shares exchanged hands on Friday’s trading session. JAKKS Pacific, a leading designer and marketer of toys and consumer products, was upgraded from Market Perform to Outperform and its price target raised from $8.00 to $10.00 by brokerage firm BMO

Crown Equity Holdings Inc Surges on CRWE-PR network Achievement (OTCMKTS:CRWE)

Crown Equity Holdings Inc Surges on CRWE-PR network Achievement (OTCMKTS:CRWE)

With today’s stock market pullback in session, you can take a look at over-the-counter securities (OTC) – Crown Equity Holdings Inc ticker symbol (OTCMKTS:CRWE). Crown Equity Holdings Inc stock price has surged today as high as +13.64% Up 0.0009, currently at +6.06% Up 0.0004, just shy of 300K shares in play in the financial market

read more

Sign Up*

Receive Our Newsletter!

 



 

 

Contacts and information

Social networks

Most popular categories

© 2014 Crown Equity Holdings Inc. All rights reserved.